Thiocolchicoside FP/IP/KP (ANSM-ASMF No.-2002-026)
Alchem International with 75 years of experience in the phytochemical space has been diligently providing plant derived ingredients, active pharmaceutical ingredients and bulk drugs to all international significant geographies.
The success of the company's operations lie in its proprietary manufacturing processes, intensive research, willingness to combat new challenges, mesh with evolving technologies ,focussed expansion and credible response to international validations and inspections.
The production sites are US FDA approved and WHO and EU GMP certified. The company has filed ASMF/DMFs in over 20 countries worldwide. Value additions through bio-technology, semi-synthesis and foot prints in the formulation space have happened in planned progression. Alchem's interest in skin care is a logical part of this dimensional growth.
Sheer Quality drives Alchem’s operations
Through perfect blend of science and nature, dedicated research, selection of finest botanical herbal extracts and focused technology, Alchem has successfully extracted the potent active molecules in the plant and offers it for pharmaceutical use to help various companies spread wellness.
Thiocolchicoside
"For pharmaceutical use, Alchem offers Thiocolchicoside with all its inherent benefits"
Thiocolchicoside is a natural derivative of colchicine and a semisynthetic derivative of the naturally occurring colchicoside extracted from the seeds of Gloriosa superba (Liliaceae). This medicinal plant has been used for a long time as a traditional medicinal herb to cure various diseases in Africa and Southeast Asia. The tuberous roots of Gloriosa superba are commonly used to cure snakebites, skin diseases and ulcers, or to treat inflammation. It is used clinically as a centrally acting muscle relaxant. It is a myorelaxant drug with anti-inflammatory and analgesic properties as well as pronounced convulsant activity.
Thiocolchicoside exhibits a selective affinity for the inhibitory gamma-aminobutyric acid and glycinergic receptors. It has an agonistic action at the spinal-strychnine-sensitive receptors that could mediate its myorelaxant effect. It has been suggested that thiocolchicoside might preferentially interact with a cortical subtype of the gamma-aminobutyric acid type A (GABAA) receptor that expresses low-affinity binding sites for GABA. The low-affinity recognition site seems to be an antagonist-binding site. This explains the proconvulsant effect of thiocolchicoside.
Thiocolchicoside is indicated for the symptomatic treatment of painful muscle spasms. It is also used in the treatment of episodic or degenerative musculoskeletal diseases such as spastic sequelae of hemiparesis, parkinson's disease and latrogenic parkinson symptoms, particularly the neurodyslectic syndrome, acute and chronic lumbar and sciatic pain, cervico-brachial neuralgia, persistent torticollis, and post-traumatic and post-operative pain.
Following oral administration, thiocolchicoside is well absorbed from the gastrointestinal tract. It shows its effect in 1-2 hours after oral administration and peak plasma level is achieved in about 0.7 hours. Its efficacy is supported not only by centuries of empirical use of its chemical predecessors, but by a representative number of well-designed clinical studies.
The product addresses broad spectrum physiological concerns and has the band width and capabilities to meet expectations. Regular use should exhibit demonstrable results to inhibit various health related issues.
